How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
DNA Origami Market
- By Application: Drug Delivery, Biosensing, Nanorobotics, Molecular Computing, Structural Biology, Diagnostics
- By Material Type: Scaffold DNA, Staple DNA, Modified DNA Strands, Peptide Nucleic Acids (PNA), Locked Nucleic Acids (LNA)
- By End-User: Pharmaceutical Companies, Biotechnology Firms, Academic and Research Institutes, Diagnostic Laboratories, Nanotechnology Companies
- By Assembly Technique: Tile-based Assembly, Scaffolded DNA Origami, DNA Brick Assembly, Hybridization Chain Reaction, Enzymatic Ligation
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Drug Delivery leads By Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 9 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.171 →
- 11 Company Profiles 9 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the DNA Origami Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 9 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
9 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Twist Bioscience Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →DNA Technologies IDT
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Tilibit Nanosystems
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Eurofins Genomics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GATTAquant DNA Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Dietz Lab
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →ADINA R&D
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Tecnalia
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.196 →Cees Dekker Lab
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Drug Delivery42.3
- Biosensing6.9
- Nanorobotics9.5
- Molecular Computing7.1
- Structural Biology15.7
- Diagnostics18.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Twist Bioscience Corporation25.2
- DNA Technologies IDT10.8
- Tilibit Nanosystems9.8
- Eurofins Genomics7.9
- GATTAquant DNA Technologies8.9
- Dietz Lab9.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.7
- Europe24.1
- Asia Pacific21.2
- Latin America12.2
- Middle East and Africa9.9
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Twist Bioscience Corporation | 80 | 76 | 97 | 92 | 88 | 79 | 85 |
| DNA Technologies IDT | 85 | 79 | 70 | 70 | 90 | 72 | 78 |
| Tilibit Nanosystems | 77 | 86 | 80 | 80 | 71 | 75 | 78 |
| Eurofins Genomics | 61 | 78 | 61 | 60 | 81 | 59 | 67 |
| GATTAquant DNA Technologies | 51 | 71 | 66 | 75 | 70 | 65 | 66 |
| Dietz Lab | 58 | 52 | 61 | 56 | 66 | 60 | 59 |
| ADINA R&D | 51 | 46 | 54 | 62 | 57 | 41 | 52 |
| Tecnalia | 43 | 52 | 52 | 55 | 50 | 55 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Twist Bioscience Corporation
- DNA Technologies IDT
- Tilibit Nanosystems
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Twist Bioscience Corporation | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| DNA Technologies IDT | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Tilibit Nanosystems | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Eurofins Genomics | ◐ | ◐ | − | ◐ | ✓ | ◐ |
| GATTAquant DNA Technologies | − | ◐ | ◐ | ◐ | − | − |
| Dietz Lab | ◐ | − | ◐ | − | − | ◐ |
| ADINA R&D | − | − | − | − | − | − |
| Tecnalia | − | − | − | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Application in North America, then scale across DNA Origami Market — a $938M beachhead inside a $12.6B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Drug Delivery
Best fit — highest urgency & budget in Application.
Biosensing
Strong fit — clear ROI and a fast path to value.
Nanorobotics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Material Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win DNA Origami Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
DNA Origami Market is a resilient opportunity — $4.50B by 2033, compounding at 4.7%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.7% CAGR
Demand compounds through 2033, outpacing GDP across Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Application moving from early to mainstream — durable secular demand.
Consolidation upside
9+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Material Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
DNA Origami Market — a $7.36B market by 2033. Plan: grow share from 8.9% to 18.3%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.9% | 18.3% | On track |
| Revenue | $645M | $1.35B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.7% | 38.6% | On track |
| Customer retention | 91.4% | 93.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Material Type capability
A defensible second engine — invest in Material Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Material Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $140M capacity & capability investment
- Greenlight bolt-on M&A in Material Type
- Authorise North America expansion plan
- Fund R&D program for Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Sales deck · value proposition
Win the DNA Origami Market conversation — a $5.40B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Application
Goal Grow share in Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your DNA Origami Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
DNA Origami Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →DNA Oligonucleotide Synthesis Service Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportTrifolirhizin Reagent Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportDNA Oligonucleotide Synthesis Market
DNA Oligonucleotide Synthesis Market is valued at USD 2.95 Billion in 2025 and is expected to r…
$3.0B market · 2025 base year
View reportDNA Nanotechnology Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportDNA Modifying Enzymes Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportDNA Modifying Agents Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportDNA Microarray Scanners Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportDNA Methyltransferase Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportDNA Methylation Sequencing Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportDNA Methylation Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportDNA Methylation Detection Kit Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportAmmonium Formate Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy